PRINCETON, NJ – 2016 年 7 月 21 日 – Certara today announced the appointment of Nathan Teuscher, PhD, to vice president of pharmacometric solutions. In his new role, Dr. Teuscher will lead the company’s Phoenix software division. He previously served as Certara’s vice president of scientific training.
Learn how modeling and simulation approaches support the goal of precision dosing—providing the right drug dose to maximize therapeutic benefit, while reducing risk for each individual patient.
PRINCETON, NJ – 2016 年 7 月 20 日 – Mitsubishi Tanabe, the 34th leading biopharmaceutical company and the tenth leading Japanese pharmaceutical company, has joined Certara’s Simcyp Consortium and licensed its proprietary Simcyp Population-based Simulator.
The topic of this webinar is to introduce mathematical tools to model PK/PD systems with distributed delays.
MBMA integrates internal and external drug development data to inform proprietary commercial and R&D decisions. The insights gained via MBMA support designing less costly and more precise trials with an eye toward achieving commercial success for both the drug and portfolio.
The use of modeling and simulation (M&S) in drug development has evolved from being a research nicety to a regulatory necessity. This paper provides a compilation of best practices to systematically leverage the many benefits of M&S across a drug development program.
Discovery drug research requires understanding complex biological, chemical, logistical and computational data from a wide variety of data sources. Certara’s D360 platform was specifically designed to meet the discovery researcher’s workflow needs.
